Victoza® (liraglutide) is a glucagon-like peptide (GLP-1) incretin hormone registered in Australia for the treatment of adults with type 2 diabetes mellitus, as an adjunct to diet and exercise.
Liraglutide stimulates glucose-dependent insulin secretion and suppresses inappropriate glucagon secretion. The potential for hypoglycaemia is low, as insulin is only released in response to high glucose levels. In addition, it also delays gastric emptying, which slows glucose absorption and decreases appetite.
Liraglutide is registered for use as a component of dual or triple combination therapy in patients with inadequate glycaemic control on oral therapy with metformin and/or a sulfonylurea. It is administered as a daily subcutaneous injection into the thigh, abdomen or upper arm. Starting at 0.6mg daily, the dose may be increased weekly up to 1.8mg daily.
The Pharmaceutical Benefits Advisory Committee determined that liraglutide 1.2mg once daily is equieffective with exenatide 10 micrograms twice daily, and recommended it for inclusion into the Pharmaceutical Benefits Scheme in 2013, which has not been implemented to date.
- Pharmaceutical Benefits Advisory Committee. Public Summary Document: Liraglutide, solution for injection, 6mg/mL, Victoza® – March 2013. Canberra: Australian Government Department of Health and Ageing; 2013.
- Rossi S (ed). Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd; 2014.
- Victoza® (liraglutide) Australian approved product information. Baulkham Hills: Novo Nordisk Pharmaceuticals Pty Limited. Approved 26 August 2010, amended 15 May 2013.
- Alderman C (ed). Liraglutide. RGH Pharmacy E-Bulletin 2013; 49 (11).